Lucian Batista de Oliveira

Prof. Lucian Batista de Oliveira

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FBFrancisco Bandeira
Francisco Bandeira
JNJaniere de Moura Nóbrega
Janiere de Moura Nóbrega
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
JBJohn Bilezikian
John Bilezikian
Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used [...] ABSTRACT Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used

16 November 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FBFrancisco Bandeira
Francisco Bandeira
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
JBJohn P. Bilezikian
John P. Bilezikian
Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up to 10 years. Those who were randomized to DMAb continued on drug, while those who were randomized to placebo transitioned to DMAb. The 10-year experience with DMAb provides data on [...] ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up to 10 years. Those who were randomized to DMAb continued on drug, while those who were randomized to placebo transitioned to DMAb. The 10-year experience with DMAb provides data on

2 November 2022 in Women's Health
Verified
Journal Article
Open access
FBFrancisco Bandeira
Francisco Bandeira
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
RCRodrigo Botelho Caldeira
Rodrigo Botelho Caldeira
LTLeticia Saldanha Toscano
Leticia Saldanha Toscano
Heart failure (HF) is a prevalent clinical syndrome that causes significant physical limitations. Osteoporosis is also an important cause of loss of functionality, and it mainly affects women. There are several reports linking HF and osteoporosis, and both share risk factors. Most of the data available so far point to bone fragility as a consequence of HF, and several mechanisms have been identified to explain this relationship. Among the proposed pathophysiological mechanisms are the hyperactivation of the renin–angiotensin–aldosterone system and the increase in parathyroid hormone, functional limitation, production of inflammatory mediators and the use of drugs for HF. The role of osteoprotegerin has gained attention owing to its cardiovascular and skeletal effects, its observed deficiency during the postmenopausal period along with its compensatory increases in HF and severe osteoporosis. The objective of this review was to perform a literature search for the main evidence on skeletal impairment in HF, with emphasis on women. As for epidemiological studies, we selected data from 3 meta-analyses and 20 individual observational studies, which together showed the interrelationship between the two clinical conditions in terms of both decreased bone density and increased fracture risk. In conclusion, HF and osteoporosis are interrelated conditions mediated by complex pathophysiological mechanisms which may be more relevant for postmenopausal women, considered to be a vulnerable population for both cardiovascular diseases and bone fragility.

1 January 2024 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
MSMariana Andrade de Figueiredo Martins Siqueira
Mariana Andrade de Figueiredo Martins Siqueira
RGRafael Buarque de Macedo Gadêlha
Rafael Buarque de Macedo Gadêlha
JGJessica Garcia
Jessica Garcia
FBFrancisco Bandeira
Francisco Bandeira
De Oliveira LB, et al. Int J Heart Fail. 2023 Nov;6:e2. https://doi.org/10.36628/ijhf.2023.0025

6 October 2025 in Acta Medica (Hradec Kralove, Czech Republic)
Verified
Journal Article
Open access
PDF file
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
VSVanessa de Oliveira E Silva
Vanessa de Oliveira E Silva
ÍJÍtalo Caio Lopes Jucá
Ítalo Caio Lopes Jucá
JTJoão Victor Gonçalves Dos Santos Torres
João Victor Gonçalves Dos Santos Torres
MTMaria Roseneide Dos Santos Torres
Maria Roseneide Dos Santos Torres
FBFrancisco Bandeira
Francisco Bandeira
Myosteatosis refers to the infiltration of fat into skeletal muscle tissue, being influenced by factors such as advanced age and overweight, which increase the inability of adipocytes to store lipids. This condition not only alters the structure of the muscle but is also associated with endocrinological imbalances such as insulin resistance (IR) and hyperinsulinemia, increasing the risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular diseases. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are effective methods for measuring myosteatosis, identifying areas of fat accumulation that may indicate specific regional patterns. This review aimed to evaluate the main evidence that associates myosteatosis with T2DM, compiling the epidemiological data already available on the subject and the main gaps in the literature. Ten observational studies were selected, from different regions of the world, which showed a relationship between myosteatosis and a higher incidence of T2DM, as well as IR, worse glycemic status, increased inflammatory mediators and a tendency to coronary artery disease. In conclusion, myosteatosis and T2DM are conditions with a relevant relationship and that have significant implications for public health, requiring greater standardization of myosteatosis assessment methods and interventional studies that address potential therapeutic strategies for this condition.

1 February 2026 in Journal of Geriatric Cardiology
Verified
Journal Article
Open access
PDF file
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
MAMarina Baltar de Albuquerque
Marina Baltar de Albuquerque
ACAmalia Pinheiro Jácome Bezerra Cavalcanti
Amalia Pinheiro Jácome Bezerra Cavalcanti
FMFábio Moura
Fábio Moura
FBFrancisco Bandeira
Francisco Bandeira
Heart failure (HF) is a complex clinical syndrome that promotes high morbidity and multi-systemic damage. Skeletal muscle can be directly affected by HF through a loss of physical capacity and various inflammatory, hormonal, and metabolic mechanisms observed in this cardiac condition, which collectively contribute to a high prevalence of sarcopenia in HF patients. Therefore, the aim of this review was to compile the main recent clinical and epidemiological data on muscle health in HF patients. Nine studies were selected from systematic reviews and clinical trials, which demonstrated a high prevalence of sarcopenia in patients with HF, particularly in males, hospitalized patients, the elderly, and those with HF with reduced ejection fraction. Oxidative stress markers and higher levels of natriuretic peptides were also observed in HF patients who exhibited damaged muscle parameters. Furthermore, the overall deterioration of prognosis in HF was associated with criteria defining sarcopenia, such as low muscle strength and lean mass loss. These findings reinforce the importance of evaluating skeletal muscle in HF patients, which can provide improvements in morbidity and functionality.